XTX Topco Ltd Invests $606,000 in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Key Points

• XTX Topco Ltd has acquired 30,929 shares of Genmab A/S, valuing the purchase at approximately $606,000.
• Barclays PLC significantly increased its stake in Genmab A/S by 1,072.8% in the last quarter, now owning 2,498 shares valued at $52,000.
• Genmab A/S has received various ratings from analysts, including a consensus rating of "Moderate Buy" and a price target of $37.80.

XTX Topco Ltd acquired a new stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 30,929 shares of the company's stock, valued at approximately $606,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in GMAB. Barclays PLC boosted its stake in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Genmab A/S in the 4th quarter valued at $60,000. Advisors Preferred LLC bought a new stake in shares of Genmab A/S during the 1st quarter valued at $84,000. Aquatic Capital Management LLC acquired a new stake in shares of Genmab A/S during the 4th quarter worth $114,000. Finally, Blue Trust Inc. increased its position in shares of Genmab A/S by 169.9% in the first quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock worth $145,000 after purchasing an additional 4,666 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Stock Performance

Genmab A/S stock traded down $1.26 during mid-day trading on Friday, hitting $21.43. 1,745,722 shares of the company traded hands, compared to its average volume of 1,458,050. The stock has a fifty day moving average price of $21.73 and a 200-day moving average price of $20.87. The stock has a market cap of $13.75 billion, a price-to-earnings ratio of 12.18, a price-to-earnings-growth ratio of 6.53 and a beta of 0.95. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $27.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. The company had revenue of $925.00 million for the quarter, compared to analysts' expectations of $5.77 billion. Sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GMAB. Truist Financial lifted their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Genmab A/S has an average rating of "Moderate Buy" and an average target price of $37.80.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.